What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Heart failure
His primary areas of investigation include Internal medicine, Cardiology, Heart failure, Myocardial infarction and Heart disease.
His work carried out in the field of Internal medicine brings together such families of science as Placebo, Endocrinology and Surgery.
His Cardiology research is multidisciplinary, relying on both Valsartan, Blood pressure and Prospective cohort study.
Aldo P. Maggioni studies Heart failure, namely Ejection fraction.
His Myocardial infarction research incorporates themes from Stroke, Aspirin, Captopril and Risk factor.
The concepts of his Heart disease study are interwoven with issues in Candesartan, Electrocardiography in myocardial infarction and Heart rate.
His most cited work include:
- ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. (5331 citations)
- 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. (3099 citations)
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (2012 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Cardiology, Heart failure, Myocardial infarction and Ejection fraction.
His study in the fields of Atrial fibrillation, Hazard ratio and Randomized controlled trial under the domain of Internal medicine overlaps with other disciplines such as In patient.
His Cardiology study incorporates themes from Stroke, Valsartan, Blood pressure and Prospective cohort study.
His Heart failure research incorporates elements of Clinical trial, Intensive care medicine, Placebo, Proportional hazards model and Heart disease.
His research on Myocardial infarction frequently connects to adjacent areas such as Surgery.
Ejection fraction connects with themes related to Tolvaptan in his study.
He most often published in these fields:
- Internal medicine (74.34%)
- Cardiology (57.17%)
- Heart failure (49.68%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (74.34%)
- Cardiology (57.17%)
- Heart failure (49.68%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Cardiology, Heart failure, Ejection fraction and In patient.
As a member of one scientific family, Aldo P. Maggioni mostly works in the field of Internal medicine, focusing on Diabetes mellitus and, on occasion, Disease.
His Cardiology research includes elements of Randomized controlled trial and Risk factor.
The Heart failure study which covers Intensive care medicine that intersects with MEDLINE.
The Atrial fibrillation study combines topics in areas such as Ablation and Cohort.
His work on Myocardial infarction is being expanded to include thematically relevant topics such as Stroke.
Between 2018 and 2021, his most popular works were:
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction (477 citations)
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction (419 citations)
- Initial invasive or conservative strategy for stable coronary disease. (390 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Heart failure
Internal medicine, Cardiology, Heart failure, Ejection fraction and Hazard ratio are his primary areas of study.
Borrowing concepts from In patient, Aldo P. Maggioni weaves in ideas under Internal medicine.
His Cardiology research is multidisciplinary, incorporating elements of Interquartile range, Randomized controlled trial, Disease and Blood pressure.
His Ventricular assist device study in the realm of Heart failure connects with subjects such as Healthcare policy.
His biological study spans a wide range of topics, including Cardiomyopathy and Clinical trial.
His study in Hazard ratio is interdisciplinary in nature, drawing from both Lower risk, Comorbidity and Renal function.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
